- Markets
- Chemicals
- TATVA
TATVA
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
India's Tatva Chintan hits record low after posting Q2 loss
** Shares of Tatva Chintan Pharma TATV.NS falls 10.6% to a record low of 821 rupees
** Specialty chemicals maker posts Q2 loss of 6.6 million rupees ($78,505.07) vs profit of 77.8 mln rupees a year ago
** TATV sees busiest day in more than a month, with over 183,000 shares traded
** Analysts' avg rating on stock is "hold" vs "buy" on peer Gujarat Fluorochemicals GUJL.NS - LSEG
** Median PT on TATV is 1,021 rupees - LSEG
** Stock down 49% YTD vs 12% gain in GUJL
($1 = 84.0710 Indian rupees)
(Reporting by Aleef Jahan in Bengaluru)
** Shares of Tatva Chintan Pharma TATV.NS falls 10.6% to a record low of 821 rupees
** Specialty chemicals maker posts Q2 loss of 6.6 million rupees ($78,505.07) vs profit of 77.8 mln rupees a year ago
** TATV sees busiest day in more than a month, with over 183,000 shares traded
** Analysts' avg rating on stock is "hold" vs "buy" on peer Gujarat Fluorochemicals GUJL.NS - LSEG
** Median PT on TATV is 1,021 rupees - LSEG
** Stock down 49% YTD vs 12% gain in GUJL
($1 = 84.0710 Indian rupees)
(Reporting by Aleef Jahan in Bengaluru)
India's Tatva Chintan rises as plant closure order revoked
** Shares of Tatva Chintan Pharma Chem TATV.NS up 2.6% to 1002 rupees, its biggest intraday pct gain since Sept. 24
** Stock set to mark first day of gains after 4 straight sessions of losses
** Co says Gujarat's pollution watchdog temporarily revokes closure direction for its Bharuch plant, and that it is in the process of resuming operations
** Avg rating of analysts on stock is "Buy," same as that on peer Gujarat Fluorochemicals GUJL.NS - LSEG
** Their median PT is 1,020.5 rupees
** Stock down 39% YTD vs 8% gain in GUJL
(Reporting by Aleef Jahan in Bengaluru)
** Shares of Tatva Chintan Pharma Chem TATV.NS up 2.6% to 1002 rupees, its biggest intraday pct gain since Sept. 24
** Stock set to mark first day of gains after 4 straight sessions of losses
** Co says Gujarat's pollution watchdog temporarily revokes closure direction for its Bharuch plant, and that it is in the process of resuming operations
** Avg rating of analysts on stock is "Buy," same as that on peer Gujarat Fluorochemicals GUJL.NS - LSEG
** Their median PT is 1,020.5 rupees
** Stock down 39% YTD vs 8% gain in GUJL
(Reporting by Aleef Jahan in Bengaluru)
Tatva Chintan Pharma Chem - Gujarat Pollution Control Board Revoked Closure Direction
Tatva Chintan Pharma Chem Ltd TATV.NS:
TATVA CHINTAN PHARMA CHEM - GUJARAT POLLUTION CONTROL BOARD REVOKED CLOSURE DIRECTION
TATVA CHINTAN PHARMA CHEM - IN PROCESS OF RESUMING OPERATIONS AT PLANT IN GUJARAT
Source text for Eikon: ID:nNSE8WfBKt
Further company coverage: TATV.NS
Tatva Chintan Pharma Chem Ltd TATV.NS:
TATVA CHINTAN PHARMA CHEM - GUJARAT POLLUTION CONTROL BOARD REVOKED CLOSURE DIRECTION
TATVA CHINTAN PHARMA CHEM - IN PROCESS OF RESUMING OPERATIONS AT PLANT IN GUJARAT
Source text for Eikon: ID:nNSE8WfBKt
Further company coverage: TATV.NS
Tatva Chintan Pharma Chem Gets Direction To Close Operations At Plant In Bharuch, Gujarat
Sept 13 (Reuters) - Tatva Chintan Pharma Chem Ltd TATV.NS:
TATVA CHINTAN PHARMA CHEM LTD - GETS DIRECTION TO CLOSE OPERATIONS AT PLANT IN BHARUCH, GUJARAT
TATVA CHINTAN PHARMA CHEM - GPCB ASKED TO SUBMIT BANK GUARANTEE OF 200,000 RUPEES
TATVA CHINTAN PHARMA CHEM - FINANCIAL IMPACT OF ORDER NOT ASCERTAINABLE AT THIS POINT
Source text for Eikon: ID:nBSEbL9Vhp
Further company coverage: TATV.NS
(([email protected];;))
Sept 13 (Reuters) - Tatva Chintan Pharma Chem Ltd TATV.NS:
TATVA CHINTAN PHARMA CHEM LTD - GETS DIRECTION TO CLOSE OPERATIONS AT PLANT IN BHARUCH, GUJARAT
TATVA CHINTAN PHARMA CHEM - GPCB ASKED TO SUBMIT BANK GUARANTEE OF 200,000 RUPEES
TATVA CHINTAN PHARMA CHEM - FINANCIAL IMPACT OF ORDER NOT ASCERTAINABLE AT THIS POINT
Source text for Eikon: ID:nBSEbL9Vhp
Further company coverage: TATV.NS
(([email protected];;))
Tatva Chintan Pharma Chem Declares Dividend 2 Rupees Per Share
May 3 (Reuters) - Tatva Chintan Pharma Chem Ltd TATV.NS:
DIVIDEND 2 RUPEES PER SHARE
Further company coverage: TATV.NS
(([email protected];))
May 3 (Reuters) - Tatva Chintan Pharma Chem Ltd TATV.NS:
DIVIDEND 2 RUPEES PER SHARE
Further company coverage: TATV.NS
(([email protected];))
India's Ami Organics rises on $60 mln fund raise plan
** Shares of Ami Organics AMIO.NS up as much as 2.8% to 1,255 rupees; last up 1.7%
** The speciality chemicals maker on Friday approved raising 5 bln rupees ($59.9 mln) via qualified institutional placement (QIP) of shares
** Average rating of five analysts covering the stock is "buy"; median PT is 1,315 rupees - LSEG data
** Including session's moves, AMIO up ~11% this year, far outpacing rivals Privi Speciality Chemicals PIVI.NS and Tatva Chintan Pharma Chem TATV.NS, which are down between 7.1%-21.8%
($1 = 83.4300 Indian rupees)
(Reporting by Navamya Ganesh Acharya in Bengaluru)
(([email protected]; +91 8805175330 ;))
** Shares of Ami Organics AMIO.NS up as much as 2.8% to 1,255 rupees; last up 1.7%
** The speciality chemicals maker on Friday approved raising 5 bln rupees ($59.9 mln) via qualified institutional placement (QIP) of shares
** Average rating of five analysts covering the stock is "buy"; median PT is 1,315 rupees - LSEG data
** Including session's moves, AMIO up ~11% this year, far outpacing rivals Privi Speciality Chemicals PIVI.NS and Tatva Chintan Pharma Chem TATV.NS, which are down between 7.1%-21.8%
($1 = 83.4300 Indian rupees)
(Reporting by Navamya Ganesh Acharya in Bengaluru)
(([email protected]; +91 8805175330 ;))
India's Tatva Chintan Pharma Chem hits record low
** Shares of Tatva Chintan Pharma Chem TATV.NS down 1.6% to record low of 1,162.80 rupees
** Reuters could not immediately determine the reason for stock move
** Stock poised for a third consecutive session of losses; eyes third straight week of decline, if trends hold
** Average rating of five analysts tracking TATV is "buy"; median PT is 1,487 rupees - LSEG data
** Including session's move, TATV is down 27.4% YTD
(Reporting by Navamya Ganesh Acharya in Bengaluru)
(([email protected]; +91 8805175330 ;))
** Shares of Tatva Chintan Pharma Chem TATV.NS down 1.6% to record low of 1,162.80 rupees
** Reuters could not immediately determine the reason for stock move
** Stock poised for a third consecutive session of losses; eyes third straight week of decline, if trends hold
** Average rating of five analysts tracking TATV is "buy"; median PT is 1,487 rupees - LSEG data
** Including session's move, TATV is down 27.4% YTD
(Reporting by Navamya Ganesh Acharya in Bengaluru)
(([email protected]; +91 8805175330 ;))
Tatva Chintan Pharma Chem Says Ankleshwar Plant Will Be Temporarily Closed For Planned Maintenance
Nov 10 (Reuters) - Tatva Chintan Pharma Chem Ltd TATV.NS:
COMPANY'S ANKLESHWAR PLANT WILL BE TEMPORARILY CLOSED FOR PLANNED MAINTENANCE
THERE WILL BE NO ADVERSE IMPACT ON OUR SUPPLY COMMITMENTS
COMPANY HAS MAINTAINED SUFFICIENT RESERVE STOCK OF ITS PRODUCTS TO MEET OUR CUSTOMERS' REQUIREMENTS
IN CASE OF SUDDEN REQUIREMENT, SAME SHALL BE MET FROM OUR DAHEJ PLANT
MAINTENANCE SHUTDOWN IS SCHEDULED TO TAKE PLACE FROM 11 NOVEMBER 2023 TO 21 NOVEMBER 2023
Source text for Eikon: ID:nBSEbrSqM6
Further company coverage: TATV.NS
(([email protected];))
Nov 10 (Reuters) - Tatva Chintan Pharma Chem Ltd TATV.NS:
COMPANY'S ANKLESHWAR PLANT WILL BE TEMPORARILY CLOSED FOR PLANNED MAINTENANCE
THERE WILL BE NO ADVERSE IMPACT ON OUR SUPPLY COMMITMENTS
COMPANY HAS MAINTAINED SUFFICIENT RESERVE STOCK OF ITS PRODUCTS TO MEET OUR CUSTOMERS' REQUIREMENTS
IN CASE OF SUDDEN REQUIREMENT, SAME SHALL BE MET FROM OUR DAHEJ PLANT
MAINTENANCE SHUTDOWN IS SCHEDULED TO TAKE PLACE FROM 11 NOVEMBER 2023 TO 21 NOVEMBER 2023
Source text for Eikon: ID:nBSEbrSqM6
Further company coverage: TATV.NS
(([email protected];))
India's Tatva Chintan Pharma Chem Sept-Quarter Consol Net Profit Rises
Nov 2 (Reuters) - Tatva Chintan Pharma Chem Ltd TATV.NS:
INDIA'S TATVA CHINTAN PHARMA CHEM LTD SEPT-QUARTER CONSOL NET PROFIT 77.8 MILLION RUPEES VERSUS PROFIT 71.1 MILLION RUPEES
TATVA CHINTAN PHARMA CHEM LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 966.7 MILLION RUPEES VERSUS 900.9 MILLION RUPEES
Source text for Eikon: ID:nBSE5sT2r5
Further company coverage: TATV.NS
(([email protected];))
Nov 2 (Reuters) - Tatva Chintan Pharma Chem Ltd TATV.NS:
INDIA'S TATVA CHINTAN PHARMA CHEM LTD SEPT-QUARTER CONSOL NET PROFIT 77.8 MILLION RUPEES VERSUS PROFIT 71.1 MILLION RUPEES
TATVA CHINTAN PHARMA CHEM LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 966.7 MILLION RUPEES VERSUS 900.9 MILLION RUPEES
Source text for Eikon: ID:nBSE5sT2r5
Further company coverage: TATV.NS
(([email protected];))
India's Tatva Chintan Pharma Chem June-Qtr Consol Net Profit Falls
Aug 4 (Reuters) - Tatva Chintan Pharma Chem Ltd TATV.NS:
INDIA'S TATVA CHINTAN PHARMA CHEM JUNE-QUARTER CONSOL NET PROFIT 95 MILLION RUPEES VERSUS PROFIT 98 MILLION RUPEES
TATVA CHINTAN PHARMA CHEM JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.14 BILLION RUPEES VERSUS 884 MILLION RUPEES
Source text for Eikon: ID:nBSE5x05cW
Further company coverage: TATV.NS
(([email protected];;))
Aug 4 (Reuters) - Tatva Chintan Pharma Chem Ltd TATV.NS:
INDIA'S TATVA CHINTAN PHARMA CHEM JUNE-QUARTER CONSOL NET PROFIT 95 MILLION RUPEES VERSUS PROFIT 98 MILLION RUPEES
TATVA CHINTAN PHARMA CHEM JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.14 BILLION RUPEES VERSUS 884 MILLION RUPEES
Source text for Eikon: ID:nBSE5x05cW
Further company coverage: TATV.NS
(([email protected];;))
India's Tatva Chintan loses 7% as analysts cut earnings estimates post Q4 profit decline
** Shares of Tatva Chintan Pharma Chem Ltd TATV.NS fall as much as 7.33%, their steepest intraday pct decline in nearly six months, to 1,695 rupees
** Speciality chemicals maker reports fall in net profit to 169.5 mln rupees ($2.1 mln) for March-qtr vs 175.1 mln rupees YoY; rev rose 26.4%
** Brokerage Nirmal Bang ("sell") says majority of TATV's portfolio is not protected, expects earnings growth to moderate in declining pricing scenario
** ICICI Securities cuts earnings estimates for FY2024 and FY2025 after results, citing near-term margin weakness
** About 44,319 shares change hands as of 10:47 a.m. IST, twice the 30-day avg - Refinitiv data
** Of five analysts tracking TATV, three maintain "buy", one suggests "sell" and one recommends "hold"; median TP is 2,400 rupees
($1 = 81.7120 Indian rupees)
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463))
** Shares of Tatva Chintan Pharma Chem Ltd TATV.NS fall as much as 7.33%, their steepest intraday pct decline in nearly six months, to 1,695 rupees
** Speciality chemicals maker reports fall in net profit to 169.5 mln rupees ($2.1 mln) for March-qtr vs 175.1 mln rupees YoY; rev rose 26.4%
** Brokerage Nirmal Bang ("sell") says majority of TATV's portfolio is not protected, expects earnings growth to moderate in declining pricing scenario
** ICICI Securities cuts earnings estimates for FY2024 and FY2025 after results, citing near-term margin weakness
** About 44,319 shares change hands as of 10:47 a.m. IST, twice the 30-day avg - Refinitiv data
** Of five analysts tracking TATV, three maintain "buy", one suggests "sell" and one recommends "hold"; median TP is 2,400 rupees
($1 = 81.7120 Indian rupees)
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463))
India's Tatva Chintan Pharma Chem Mar-Quarter Consol Net Profit Falls
May 5 (Reuters) - Tatva Chintan Pharma Chem Ltd TATV.NS:
MAR-QUARTER CONSOL NET PROFIT 169.5 MILLION RUPEES VERSUS PROFIT 175.1 MILLION RUPEES
MAR-QUARTER CONSOL REVENUE FROM OPERATIONS 1.25 BILLION RUPEES VERSUS 985.3 MILLION RUPEES
DIVIDEND OF 2 RUPEES PER SHARE
Source text for Eikon: ID:nBSE3G6wRl
Further company coverage: TATV.NS
(([email protected];))
May 5 (Reuters) - Tatva Chintan Pharma Chem Ltd TATV.NS:
MAR-QUARTER CONSOL NET PROFIT 169.5 MILLION RUPEES VERSUS PROFIT 175.1 MILLION RUPEES
MAR-QUARTER CONSOL REVENUE FROM OPERATIONS 1.25 BILLION RUPEES VERSUS 985.3 MILLION RUPEES
DIVIDEND OF 2 RUPEES PER SHARE
Source text for Eikon: ID:nBSE3G6wRl
Further company coverage: TATV.NS
(([email protected];))
Events:
Dividend
Dividend
Dividend
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Tatva Chintan Pharma do?
Tatva Chintan Pharma Chem Limited is a leading global manufacturer of specialty chemicals like structure directing agents and electrolyte salts for super capacitor batteries, serving industries such as pharmaceuticals and agrochemicals.
Who are the competitors of Tatva Chintan Pharma?
Tatva Chintan Pharma major competitors are Paushak, Ultramar & Pigments, Valiant Organics, 20 Microns, Sadhana Nitro Chem, DMCC Speciality Chem, Chemcon Speciality. Market Cap of Tatva Chintan Pharma is ₹1,737 Crs. While the median market cap of its peers are ₹809 Crs.
Is Tatva Chintan Pharma financially stable compared to its competitors?
Tatva Chintan Pharma seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Tatva Chintan Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Tatva Chintan Pharma latest dividend payout ratio is 15.41% and 3yr average dividend payout ratio is 9.93%
How has Tatva Chintan Pharma allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery
How strong is Tatva Chintan Pharma balance sheet?
Balance sheet of Tatva Chintan Pharma is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Tatva Chintan Pharma improving?
No, profit is decreasing. The profit of Tatva Chintan Pharma is ₹14.3 Crs for TTM, ₹30.35 Crs for Mar 2024 and ₹45.49 Crs for Mar 2023.
Is the debt of Tatva Chintan Pharma increasing or decreasing?
Yes, The debt of Tatva Chintan Pharma is increasing. Latest debt of Tatva Chintan Pharma is ₹0.36 Crs as of Sep-24. This is greater than Mar-24 when it was -₹62.23 Crs.
Is Tatva Chintan Pharma stock expensive?
Tatva Chintan Pharma is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Tatva Chintan Pharma is 121, while 3 year average PE is 87.59. Also latest EV/EBITDA of Tatva Chintan Pharma is 42.51 while 3yr average is 51.74.
Has the share price of Tatva Chintan Pharma grown faster than its competition?
Tatva Chintan Pharma has given lower returns compared to its competitors. Tatva Chintan Pharma has grown at ~-33.09% over the last 3yrs while peers have grown at a median rate of -16.16%
Is the promoter bullish about Tatva Chintan Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Tatva Chintan Pharma is 72.02% and last quarter promoter holding is 72.02%.
Are mutual funds buying/selling Tatva Chintan Pharma?
The mutual fund holding of Tatva Chintan Pharma is decreasing. The current mutual fund holding in Tatva Chintan Pharma is 5.34% while previous quarter holding is 6.26%.